Luke J. Laffin, MD

CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.

A multinational collaborative report of global disease trends and risk factors shows CVD remains the leading cause of death and hypertension remains the leading modifiable risk factor for premature CV death worldwide, researchers reported.

CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well tolerated in patients with resistant hypertension, according to results of the PRECISION trial.